Imexpharm Corporation (HOSE:IMP)
54,000
-100 (-0.18%)
At close: Feb 9, 2026
Imexpharm Balance Sheet
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 189,193 | 161,983 | 106,201 | 178,845 | 271,273 |
Short-Term Investments | 212,102 | 142,000 | 93,000 | 211,300 | 111,300 |
Trading Asset Securities | - | - | - | - | 1,153 |
Cash & Short-Term Investments | 401,296 | 303,983 | 199,201 | 390,145 | 383,726 |
Cash Growth | 32.01% | 52.60% | -48.94% | 1.67% | 157.75% |
Accounts Receivable | 323,278 | 334,746 | 254,058 | 228,770 | 241,946 |
Other Receivables | 38,672 | 4,030 | 4,066 | -1,000 | 11,995 |
Receivables | 361,950 | 338,776 | 258,124 | 227,770 | 255,941 |
Inventory | 677,715 | 705,082 | 699,446 | 435,841 | 492,075 |
Prepaid Expenses | 21,304 | 15,564 | 6,539 | 1,601 | 3,155 |
Other Current Assets | 45,147 | 46,139 | 43,825 | 48,195 | 41,443 |
Total Current Assets | 1,507,411 | 1,409,544 | 1,207,135 | 1,103,553 | 1,176,340 |
Property, Plant & Equipment | 745,246 | 828,489 | 908,754 | 996,450 | 955,680 |
Long-Term Investments | 66,959 | 66,959 | 71,284 | 71,290 | 50,962 |
Other Intangible Assets | 73,215 | 74,219 | 74,150 | 72,978 | 73,581 |
Other Long-Term Assets | 389,804 | 125,566 | 131,293 | 32,672 | 38,136 |
Total Assets | 2,782,634 | 2,504,777 | 2,392,615 | 2,276,944 | 2,294,700 |
Accounts Payable | 80,783 | 77,044 | 70,505 | 87,542 | 92,713 |
Accrued Expenses | 102,784 | 89,231 | 144,776 | 139,803 | 100,346 |
Short-Term Debt | 112,779 | 86,122 | 49,422 | - | 80,491 |
Current Portion of Long-Term Debt | - | - | - | 94,980 | 91,652 |
Current Income Taxes Payable | 27,727 | 31,631 | 19,107 | 25,382 | 17,141 |
Other Current Liabilities | 48,360 | 37,630 | 24,227 | 34,789 | 26,295 |
Total Current Liabilities | 372,432 | 321,657 | 308,036 | 382,497 | 408,638 |
Long-Term Debt | 100,000 | - | - | - | 91,652 |
Other Long-Term Liabilities | 3,680 | - | - | - | - |
Total Liabilities | 476,112 | 321,657 | 308,036 | 382,497 | 500,290 |
Common Stock | 1,540,428 | 1,540,428 | 700,384 | 667,054 | 667,054 |
Additional Paid-In Capital | 187,323 | 187,323 | 507,368 | 507,368 | 507,368 |
Retained Earnings | 576,709 | 453,306 | 874,764 | 717,963 | 617,926 |
Treasury Stock | -358.6 | -358.6 | -358.6 | -358.6 | -358.6 |
Comprehensive Income & Other | 2,421 | 2,421 | 2,421 | 2,421 | 2,421 |
Shareholders' Equity | 2,306,522 | 2,183,119 | 2,084,579 | 1,894,447 | 1,794,410 |
Total Liabilities & Equity | 2,782,634 | 2,504,777 | 2,392,615 | 2,276,944 | 2,294,700 |
Total Debt | 212,779 | 86,122 | 49,422 | 94,980 | 263,795 |
Net Cash (Debt) | 188,516 | 217,862 | 149,779 | 295,165 | 119,931 |
Net Cash Growth | -13.47% | 45.46% | -49.26% | 146.11% | 568.18% |
Net Cash Per Share | 1224.06 | 1414.60 | 972.53 | 1916.53 | 778.71 |
Filing Date Shares Outstanding | 154.01 | 154.01 | 154.01 | 154.01 | 154.01 |
Total Common Shares Outstanding | 154.01 | 154.01 | 154.01 | 154.01 | 154.01 |
Working Capital | 1,134,979 | 1,087,886 | 899,099 | 721,056 | 767,702 |
Book Value Per Share | 14976.55 | 14175.27 | 13535.33 | 12300.70 | 11651.16 |
Tangible Book Value | 2,233,308 | 2,108,900 | 2,010,429 | 1,821,469 | 1,720,829 |
Tangible Book Value Per Share | 14501.15 | 13693.36 | 13053.86 | 11826.85 | 11173.39 |
Buildings | 385,312 | 384,650 | 384,597 | 299,061 | 298,602 |
Machinery | 1,101,466 | 1,088,549 | 1,066,310 | 638,041 | 601,972 |
Construction In Progress | 37,418 | 43,897 | 47,351 | 580,743 | 519,463 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.